Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

⟵ Back to Search Results

Beigene Study ID

BGB-A317-315

ClinicalTrials.gov ID

NCT04379635

China Drug Trials ID

CTR20200821

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents